Revolution Medicines financials at a glance

+ Portfolio

The revenue of Revolution Medicines is reported as 0.01158 billion Dollars in the fiscal year 2023. The earnings were -3.86 Dollars per share in 2023, which was 25.32 lower than 2022. And about -0.3583 billion Dollars are reported as free cash flow in the financials of Revolution Medicines 2023. No dividends were paid to the shareholders of the Revolution Medicines stock NasdaqGS:RVMD in the financial year 2023.

$11.58M

Revenue

$-3.86

Earnings Per Share

100.00%

Gross Margin %

$-,334.50M

Free Cash Flow

Revenue

11.58

Earnings Per Share

-3.86

Gross Margin %

100.00

Free Cash Flow

-,334.50

Financials

Year	Year	TTM	2023	2022	2021	2020	2019
Rev.	Revenue	N/A	$11.58M	$35.38M	$29.39M	$42.98M	$50.04M
GM %	Gross Margin %	0.00%	100.00%	0.00%	100.00%	-,207.68%	-83.36%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	-,257.54%	-,108.15%
EPS	Earnings Per Share	$-3.31	$-3.86	$-3.08	$-2.57	$-2.01	$-1.05
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	0	0
Sha.	Shares	N/AM	164.69M	90.49M	74.19M	73.38M	59M
OCF	Operating Cash Flow	N/A	$-,350.57M	$-,224.40M	$-,147.18M	$-,100.37M	$-49.62M
FCF	Free Cash Flow	N/A	$-,334.50M	$-,235.22M	$-,153.71M	$-,103.00M	$-52.21M
FCFS	Free Cash Flow Per Share	$-3.00	$-3.17	$-2.92	$-2.11	$-1.88	$-16.66

Revolution Medicines financials at a glance

Financials

Discover